Enlivex Therapeutics (ENLV) Competitors

$0.70 -0.02 (-3.23%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$0.70 +0.00 (+0.53%)

As of 05:16 AM Eastern

ENLV vs. ACRS, GYRE, CYRX, CTMX, and STRO

Should you buy Enlivex Therapeutics stock or one of its competitors? MarketBeat compares Enlivex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enlivex Therapeutics include Aclaris Therapeutics (ACRS), Gyre Therapeutics (GYRE), CryoPort (CYRX), CytomX Therapeutics (CTMX), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry.

How does Enlivex Therapeutics compare to Aclaris Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Enlivex Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Enlivex Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Aclaris Therapeutics	$7.83M	78.48	-$64.92M	-$0.56	N/A

Enlivex Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Enlivex Therapeutics' return on equity of 248.08% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enlivex Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 2,266.27%. Aclaris Therapeutics has a consensus price target of $11.29, indicating a potential upside of 156.49%. Given Enlivex Therapeutics' higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Aclaris Therapeutics had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 7 mentions for Aclaris Therapeutics and 3 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.94 beat Aclaris Therapeutics' score of -0.02 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Enlivex Therapeutics beats Aclaris Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Gyre Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Gyre Therapeutics had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 6 mentions for Gyre Therapeutics and 3 mentions for Enlivex Therapeutics. Gyre Therapeutics' average media sentiment score of 1.08 beat Enlivex Therapeutics' score of 0.94 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market.

Enlivex Therapeutics has higher earnings, but lower revenue than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Gyre Therapeutics	$116.59M	5.36	$5.03M	-$0.09	N/A

Enlivex Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 2,266.27%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 163.98%. Given Enlivex Therapeutics' higher probable upside, equities research analysts clearly believe Enlivex Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Enlivex Therapeutics' return on equity of 248.08% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Gyre Therapeutics	-5.44%	3.13%	2.67%

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 10.0% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Enlivex Therapeutics and Gyre Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Enlivex Therapeutics compare to CryoPort?

Enlivex Therapeutics (NASDAQ:ENLV) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Enlivex Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Enlivex Therapeutics has higher earnings, but lower revenue than CryoPort. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
CryoPort	$176.18M	3.81	$78.30M	$1.35	9.86

In the previous week, Enlivex Therapeutics had 2 more articles in the media than CryoPort. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 1 mentions for CryoPort. Enlivex Therapeutics' average media sentiment score of 0.94 beat CryoPort's score of 0.71 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 2,266.27%. CryoPort has a consensus price target of $14.44, suggesting a potential upside of 8.47%. Given Enlivex Therapeutics' higher probable upside, equities research analysts plainly believe Enlivex Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 10.1% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CryoPort has a net margin of 41.57% compared to Enlivex Therapeutics' net margin of 0.00%. Enlivex Therapeutics' return on equity of 248.08% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
CryoPort	41.57%	-7.92%	-4.79%

Summary

CryoPort beats Enlivex Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to CytomX Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, CytomX Therapeutics had 9 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 12 mentions for CytomX Therapeutics and 3 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.94 beat CytomX Therapeutics' score of 0.82 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Enlivex Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 2,266.27%. CytomX Therapeutics has a consensus price target of $12.78, suggesting a potential upside of 265.08%. Given Enlivex Therapeutics' higher possible upside, research analysts plainly believe Enlivex Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Enlivex Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

Enlivex Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Enlivex Therapeutics' return on equity of 248.08% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Enlivex Therapeutics has higher earnings, but lower revenue than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
CytomX Therapeutics	$76.20M	7.82	-$17.37M	-$0.41	N/A

Summary

Enlivex Therapeutics beats CytomX Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Enlivex Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Enlivex Therapeutics' return on equity of 248.08% beat Sutro Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Enlivex Therapeutics	N/A	248.08%	206.39%

Enlivex Therapeutics has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	5.58	-$191.09M	-$17.20	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

Sutro Biopharma has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Sutro Biopharma currently has a consensus target price of $48.25, suggesting a potential upside of 39.94%. Enlivex Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 2,266.27%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sutro Biopharma had 2 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for Sutro Biopharma and 3 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.94 beat Sutro Biopharma's score of 0.05 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 5.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Enlivex Therapeutics beats Sutro Biopharma on 9 of the 16 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENLV vs. The Competition

Export

Metric	Enlivex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$171.06M	$3.00B	$6.25B	$12.29B
Dividend Yield	N/A	1.98%	2.80%	5.30%
P/E Ratio	-1.27	17.22	20.86	25.23
Price / Sales	N/A	284.56	554.89	80.24
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	0.09	3.93	9.69	6.63
Net Income	$1.24B	$74.99M	$3.56B	$335.59M
7 Day Performance	-6.94%	-4.47%	-1.64%	-1.20%
1 Month Performance	-18.87%	-7.93%	-2.60%	-1.16%
1 Year Performance	-29.57%	29.34%	30.07%	28.10%

Enlivex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENLV Enlivex Therapeutics	2.6495 of 5 stars	$0.70 -3.2%	$16.50 +2,266.3%	-30.3%	$171.06M	N/A	N/A	70	News Coverage
ACRS Aclaris Therapeutics	2.5273 of 5 stars	$4.88 -1.4%	$11.29 +131.3%	+235.9%	$691.34M	$7.83M	N/A	100	Analyst Upgrade
GYRE Gyre Therapeutics	2.9311 of 5 stars	$7.30 +3.0%	$17.00 +132.9%	-43.3%	$687.93M	$116.59M	236.33	40	Positive News Analyst Downgrade
CYRX CryoPort	3.2313 of 5 stars	$13.04 -1.0%	$14.44 +10.7%	+99.3%	$663.80M	$176.18M	9.66	1,186	Gap Down
CTMX CytomX Therapeutics	3.1996 of 5 stars	$3.88 +0.5%	$12.78 +229.3%	+72.4%	$656.92M	$76.20M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. ACRS, GYRE, CYRX, CTMX, and STRO

How does Enlivex Therapeutics compare to Aclaris Therapeutics?

Summary

How does Enlivex Therapeutics compare to Gyre Therapeutics?

Summary

How does Enlivex Therapeutics compare to CryoPort?

Summary

How does Enlivex Therapeutics compare to CytomX Therapeutics?

Summary

How does Enlivex Therapeutics compare to Sutro Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. ACRS, GYRE, CYRX, CTMX, and STRO

How does Enlivex Therapeutics compare to Aclaris Therapeutics?

Which has more volatility & risk, ENLV or ACRS?

Which has preferable valuation and earnings, ENLV or ACRS?

Is ENLV or ACRS more profitable?

Do insiders & institutionals believe in ENLV or ACRS?

Do analysts prefer ENLV or ACRS?

Does the media refer more to ENLV or ACRS?

Summary

How does Enlivex Therapeutics compare to Gyre Therapeutics?

Does the media refer more to ENLV or GYRE?

Which has more risk and volatility, ENLV or GYRE?

Which has stronger earnings & valuation, ENLV or GYRE?

Do analysts prefer ENLV or GYRE?

Is ENLV or GYRE more profitable?

Do insiders and institutionals believe in ENLV or GYRE?

Summary

How does Enlivex Therapeutics compare to CryoPort?

Which has more risk and volatility, ENLV or CYRX?

Which has better valuation & earnings, ENLV or CYRX?

Does the media favor ENLV or CYRX?

Do analysts rate ENLV or CYRX?

Do insiders and institutionals have more ownership in ENLV or CYRX?

Is ENLV or CYRX more profitable?

Summary

How does Enlivex Therapeutics compare to CytomX Therapeutics?

Does the media refer more to ENLV or CTMX?

Do institutionals and insiders have more ownership in ENLV or CTMX?

Do analysts rate ENLV or CTMX?

Which has more volatility & risk, ENLV or CTMX?

Is ENLV or CTMX more profitable?

Which has stronger valuation and earnings, ENLV or CTMX?

Summary

How does Enlivex Therapeutics compare to Sutro Biopharma?

Is STRO or ENLV more profitable?

Which has higher earnings and valuation, STRO or ENLV?

Which has more risk & volatility, STRO or ENLV?

Do analysts prefer STRO or ENLV?

Does the media refer more to STRO or ENLV?

Do institutionals & insiders hold more shares of STRO or ENLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools